Second quarter Tuberculosis (TB) revenue growth of 17%, with record TB revenue in the United States Gross margin improved by 450 basis points compared to prior year period and 630 basis points on a sequential basis Launch of transformative T-Cell Select™ product to enable full automation of T-SPOT
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced the launch of the new CE-marked T-Cell Select kit in Europe and select ROW countries.
OXFORD, United Kingdom and MARLBOROUGH, Mass. , July 17, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it plans to release second quarter 2018 financial results prior to market open on Tuesday, July 31, 2018 . Dr.
OXFORD, United Kingdom and MARLBOROUGH, Mass. , June 05, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it applauds updated guidelines from the American Academy of Pediatrics (AAP) on screening for latent
OXFORD, United Kingdom and MARLBOROUGH, Mass. , June 04, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that data from studies utilizing the T-SPOT. CMV test will be presented at the American Transplant Congress (ATC)
OXFORD, United Kingdom and MARLBOROUGH, Mass. , May 29, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Rick Altieri , Chief Financial Officer, will present at the Jefferies 2018 Healthcare Conference on Tuesday,
OXFORD, United Kingdom and MARLBOROUGH, Mass. , May 21, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that the Company’s T-SPOT. TB test for tuberculosis (TB) infection has been included in the World Health
OXFORD, United Kingdom and MARLBOROUGH, Mass. , May 16, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith , Chief Executive Officer, will present at the 2018 UBS Global Healthcare Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass. , May 01, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced first quarter 2018 financial results. “Our first quarter results were in line with our expectations, with
OXFORD, United Kingdom and MARLBOROUGH, Mass. , April 17, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it plans to release first quarter 2018 financial results prior to market open on Tuesday, May 1 , 2018. Dr.
Harnessing the power of T cell measurement
